Current Support
Completed Support
Society for Pediatric Sedation, “Transitioning pediatric circumcision from the operating room to the pediatric sedation center: a pilot study” (2022-2023). Boriosi, Co-PI
Purdue Pharma, “A multicenter, inpatient, open-label study to characterize the pharmacokinetics, safety, and efficacy of intravenous dosing of
Buprenorphine in pediatric patients aged from birth to 6 years of age (inclusive) who require opioid analgesia for acute moderate to severe pain (BUP 3030)” (2011-2014). Boriosi, Site PI
Isomark, LLC, “Changes in 13CO2/12CO2 delta” (2011-2012). Boriosi, PI
Hoffmann-LaRoche, Inc., “An open label prospective, pharmacokinetic/pharmacodynamics and safety evaluation of intravenous oseltamivir (Tamiflu ®) in the treatment of infants less than one year of age with influenza infection, protocol no. NP25138C” (2010-2013). Boriosi, PI
Hoffmann-LaRoche, Inc., “An open label prospective, pharmacokinetic/pharmacodynamics and safety evaluation of intravenous oseltamivir (Tamiflu ®) in the treatment of children 1 to 12 years of age with influenza infection, protocol no. NP25139C” (2010-2013). Boriosi, PI
NIH/NHLBl and the University of California-San Francisco (K23 HL085526), “Targeted genomic analysis of coagulation pathway in acute lung injury (ALI)” (2010-2013). Boriosi, Co-Investigator
Hospira Pharmaceutical, “A phase III, randomized, double-blind, dose-controlled, multi-center study evaluating the safety and efficacy of dexmedetomidine in initially intubated and mechanically ventilated pediatric intensive care unit subjects” (2009-2011). Boriosi, PI
Charlotte Coleman Frey Foundation, “Efficacy and safety of lung recruitment in pediatric patients with acute lung injury” (2006-2009). Boriosi, PI